Effect of a new and specific PAF-antagonist, WEB 2086, on PAF and endotoxin/tumor necrosis factor induced changes in mortality and intestinal transit velocity.
Heuer
H
H
Dept. of Pharmacology, Boehringer Ingelheim KG, Ingelheim, FRG.
D000818:Animals; D001381:Azepines / Q000494:pharmacology*; D004357:Drug Synergism; D004731:Endotoxins / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D005769:Gastrointestinal Motility / Q000187:drug effects*; D051379:Mice; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology*; D014230:Triazoles; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity
D001381:Azepines; D004731:Endotoxins; D010972:Platelet Activating Factor; D014227:Triazines; D014230:Triazoles; D014409:Tumor Necrosis Factor-alpha; C052518:WEB 2086